LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Shukui Qin, Masashi Kudo, T Meyer, RS Finn, Peter Vogel, Yibing Bai, Y. Guo, Zhefeng Meng, T. Zhang, Takeshi Satoh, A. Hiraoka, Donatella Marino, Éric Assenat, Lucjan Wyrwicz, Miriam Campos, K. Hsing-Tao, F. Boisserie, Shuang Li, Y. Chen, Andrew X. Zhu
Topics & Concepts
MedicineSorafenibClinical endpointInternal medicineHepatocellular carcinomaPhases of clinical researchResponse Evaluation Criteria in Solid TumorsGastroenterologyRandomized controlled trialSurgeryOncologyClinical trialAdvanced Breast Cancer TherapiesHepatocellular Carcinoma Treatment and PrognosisLung Cancer Research Studies